MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.03.06.710248

Медицинская библиотека · bioRxiv : the preprint server for biology · 2026

A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways.

Tan Mingdian, Schow Steve, Liu Yi, Lum Robert, Massoudi Dawiyat, Dhanasekaran Renumathy, So Samuel, Chua Mei-Sze

СтатьяПрепринтПеревод в очереди

Аннотация

BACKGROUND

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for effective therapies. The FDA-approved anthelmintic, niclosamide, is a promising repurposed drug candidate for HCC; however, its clinical application in solid tumors is hampered by poor aqueous solubility and resulting low bioavailability.

METHODS

We designed and screened eight novel niclosamide prodrug candidates for solubility, stability, and anti-proliferative activity in HCC cell lines. The lead compound, SSL-0024, was evaluated for pharmacokinetics and anti-tumor efficacy in an orthotopic patient-derived xenograft (PDX) model, and for cytotoxicity in patient-derived organoids (PDOs). Mechanistic studies assessed AKT-mTOR-STAT3 and other related signaling pathways.

RESULTS

The O-sulfate derivative, SSL-0024, demonstrated improved solubility and pH stability, and a sustained release of niclosamide over ~48 h. Once-daily oral administration of SSL-0024 (100 mg/kg) achieved ~60% tumor growth inhibition in PDX models at ~46.8% of the niclosamide ethanolamine dose, with minimal toxicity. It also induced significantly greater cytotoxicity than sorafenib (p<0.05) in the PDO. Mechanistically, SSL-0024 suppressed major oncogenic pathways including AKT-mTOR-STAT3, RAF, and Wnt/β-catenin.

CONCLUSIONS

SSL-0024 overcomes key pharmacokinetic limitations of niclosamide while maintaining potent anti-tumor activity, supporting its further development as an orally bioavailable therapeutic candidate for HCC.

Для цитирования: Tan Mingdian, Schow Steve, Liu Yi, Lum Robert, Massoudi Dawiyat, Dhanasekaran Renumathy, So Samuel, Chua Mei-Sze. A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways.. bioRxiv : the preprint server for biology. 2026. DOI: 10.64898/2026.03.06.710248.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.